ORIC Pharmaceuticals, Inc.
ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.07
Price-4.90%
-$0.57
1Y
Price
Market Cap
$1.146b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$135.214m
-5.8%
1y CAGR-15.2%
3y CAGR-14.7%
5y CAGREPS
-$1.44
+5.5%
1y CAGR+8.3%
3y CAGR+4.1%
5y CAGRBook Value
$415.557m
$436.762m
Assets$21.205m
Liabilities$3.296m
DebtDebt to Assets
0.8%
-
Debt to EBITDAFree Cash Flow
-$111.362m
-3.2%
1y CAGR-15.6%
3y CAGR-18.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company